Yihuan Xu

1.4k total citations
20 papers, 1.1k citations indexed

About

Yihuan Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yihuan Xu has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Yihuan Xu's work include Gastric Cancer Management and Outcomes (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Yihuan Xu is often cited by papers focused on Gastric Cancer Management and Outcomes (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Yihuan Xu collaborates with scholars based in United States, United Kingdom and Japan. Yihuan Xu's co-authors include Peter A. McCue, Kristin L. Brill, Pauline K. Park, Gloria J. Morris, Anne Rosenberg, Allan Topham, Edith P. Mitchell, Gordon F. Schwartz, Jonathan D. Schwartz and Rebecca R. Hozak and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Yihuan Xu

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yihuan Xu United States	11	559	360	331	249	236	20	1.1k
Maria Pia Morelli United States	19	863 1.5×	350 1.0×	449 1.4×	272 1.1×	355 1.5×	70	1.3k
Manish Gala United States	15	405 0.7×	316 0.9×	457 1.4×	235 0.9×	140 0.6×	32	1.1k
Emanuele Valtorta Italy	16	661 1.2×	357 1.0×	531 1.6×	258 1.0×	331 1.4×	40	1.2k
Anne Trinh United States	13	882 1.6×	483 1.3×	563 1.7×	485 1.9×	220 0.9×	27	1.4k
Byung Woog Kang South Korea	19	508 0.9×	347 1.0×	468 1.4×	239 1.0×	198 0.8×	77	1.2k
Teresa Di Desidero Italy	24	542 1.0×	200 0.6×	421 1.3×	91 0.4×	253 1.1×	52	1.1k
Giorgia Migliardi Italy	18	719 1.3×	277 0.8×	515 1.6×	180 0.7×	352 1.5×	28	1.3k
Frédérique Penault‐Llorca France	7	821 1.5×	242 0.7×	327 1.0×	359 1.4×	370 1.6×	14	1.1k
Cristina Santos Spain	20	1.1k 2.0×	312 0.9×	479 1.4×	375 1.5×	284 1.2×	51	1.7k
Sandra Zazo Spain	19	564 1.0×	383 1.1×	860 2.6×	125 0.5×	161 0.7×	58	1.3k

Countries citing papers authored by Yihuan Xu

Since Specialization

Citations

This map shows the geographic impact of Yihuan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yihuan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yihuan Xu more than expected).

Fields of papers citing papers by Yihuan Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yihuan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yihuan Xu. The network helps show where Yihuan Xu may publish in the future.

Co-authorship network of co-authors of Yihuan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yihuan Xu. A scholar is included among the top collaborators of Yihuan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yihuan Xu. Yihuan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krieger, Stephen, et al.. (2024). MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide (P3-6.001). Neurology. 102(7_supplement_1).

Lu, Jialin, et al.. (2024). CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomarker Research. 12(1). 86–86. 34 indexed citations

Álvarez, Enrique, Lawrence Steinman, Edward Fox, et al.. (2024). Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis. Frontiers in Neurology. 15. 1473284–1473284. 1 indexed citations

Steinman, Lawrence, Edward Fox, Hans‐Peter Hartung, et al.. (2022). Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine. 387(8). 704–714. 111 indexed citations

Xu, Jianming, Ken Kato, Richard Hubner, et al.. (2019). A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology. 37(15_suppl). TPS2656–TPS2656. 3 indexed citations

Zhu, Andrew X., Peter R. Galle, Masatoshi Kudo, et al.. (2018). A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).. Journal of Clinical Oncology. 36(4_suppl). TPS538–TPS538. 25 indexed citations

Masuda, Norikazu, Hiroji Iwata, Kenjiro Aogi, et al.. (2016). Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Japanese Journal of Clinical Oncology. 46(12). 1088–1094. 6 indexed citations

Fuchs, Charles S., Josep Tabernero, Salah‐Eddin Al‐Batran, et al.. (2016). A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology. 34(4_suppl). TPS178–TPS178. 8 indexed citations

Xu, Yihuan & Boris Iglewicz. (2015). False Discovery Versus Familywise Error Rate Approaches to Outlier Detection. Statistics in Biopharmaceutical Research. 8(2). 143–150. 1 indexed citations

10.

Fuchs, Charles S., Josep Tabernero, Salah-Eddin Al-Batran, et al.. (2015). A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology. 33(15_suppl). TPS4131–TPS4131. 6 indexed citations

11.

Yoon, Harry H., Johanna C. Bendell, Fadi S. Braiteh, et al.. (2014). Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.. Journal of Clinical Oncology. 32(15_suppl). 4004–4004. 64 indexed citations

12.

Xu, Yihuan, Boris Iglewicz, & Inna Chervoneva. (2014). Robust estimation of the parameters of -and- distributions, with applications to outlier detection. Computational Statistics & Data Analysis. 75. 66–80. 11 indexed citations

13.

García, Jorge A., Gary R. Hudes, Toni K. Choueiri, et al.. (2014). A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 120(11). 1647–1655. 26 indexed citations

14.

Penson, Richard T., Kathleen N. Moore, Gini F. Fleming, et al.. (2014). A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecologic Oncology. 134(3). 478–485. 26 indexed citations

15.

Yardley, Denise A., Paul Richards, James A. Reeves, et al.. (2014). Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32(15_suppl). 1035–1035. 16 indexed citations

16.

Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations

17.

Penson, Richard T., Kathleen N. Moore, Gini F. Fleming, et al.. (2012). A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162).. Journal of Clinical Oncology. 30(15_suppl). 5012–5012. 7 indexed citations

18.

Valicenti, Richard K., et al.. (2010). A Phase I Trial of Samarium-153-Lexidronam Complex for Treatment of Clinically Nonmetastatic High-Risk Prostate Cancer: First Report of a Completed Study. International Journal of Radiation Oncology*Biology*Physics. 79(3). 732–737. 7 indexed citations

19.

Li, Peng, Stephanie Schulz, Alessandro Bombonati, et al.. (2007). Guanylyl Cyclase C Suppresses Intestinal Tumorigenesis by Restricting Proliferation and Maintaining Genomic Integrity. Gastroenterology. 133(2). 599–607. 116 indexed citations

20.

Morris, Gloria J., Allan Topham, Yihuan Xu, et al.. (2007). Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer. 110(4). 876–884. 477 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact